GFAP and Parkinson disease: In the PD animal model, OYF reversed the motor behavioural dysfunction, upregulated the tyrosine hydroxylase (TH) expression, decreased the immunoreactivity of ionized calcium-binding adapter molecule 1 (Iba-1) and glial fibrillary acidic protein (GFAP), and downregulated the mRNA levels of TNF-α and COX-2.